Filing summary
Entity and period: The supplied filing is Brilliant Acquisition Corporation’s Form 10-K for the fiscal year ended December 31, 2022—not a filing identified as T3 Defense Inc. It describes a British Virgin Islands blank-check company (SPAC), not an operating defense business. The filing was signed March 10, 2023.
Business context and transaction
The company had no operating business or revenue and was seeking an initial business combination. In February 2022, it agreed to combine with Nukkleus Inc.; the merger agreement was amended, including in September 2022 and January 2023. Completion was not assured. Shareholders repeatedly extended the SPAC deadline, and the filing describes a further extension through April 23, 2023, subject to required trust-account funding. If no combination or further extension occurred by the deadline, the company would have to wind up and redeem public shares.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Operating costs | $1,202,399 | $670,916 |
| Net loss | $967,614 | $599,127 |
| Basic and diluted loss per share | $0.21 | $0.10 |
| Net cash used in operating activities | $1,132,761 | $430,914 |
2022 other income included $169,836 from a decrease in the fair value of warrant liabilities and $64,949 of interest income. The loss widened as operating costs increased; the warrant remeasurement gain partly offset those costs. Revenue-based margins are not applicable because the company had no operations or revenue.
At December 31, 2022, total assets were $6,111,545, including $6,055,018 in the trust account and $55,789 of operating cash. Current liabilities were $3,965,850, including $2,680,227 in related-party promissory notes and $970,600 due to a related party; total liabilities were $3,976,493. There was no reported long-term debt. The company reported a $1,229,096 working-capital deficit excluding trust-account cash. The trust balance represented approximately $10.77 per public share at year-end.
Cash flows included $47,387,687 of proceeds from trust investments and $42,453,015 of redemptions of 4,035,064 shares. These large investing and financing flows principally reflect the SPAC trust and shareholder redemptions, not operating-business cash generation.
Changes, outlook and significant risks
- Operating costs increased from $670,916 to $1,202,399, and net loss increased from $599,127 to $967,614 year over year.
- Redemptions materially reduced the trust account and public float. The filing reports $6.1 million remaining in trust at year-end, with substantial additional redemptions and funding activity disclosed after year-end.
- Management and the auditor both identified substantial doubt about the company’s ability to continue as a going concern, given limited cash outside the trust, its working-capital deficit, and the approaching business-combination deadline. The financial statements include no liquidation adjustments.
- The company reported ineffective internal control over financial reporting due to a material weakness in accounting for complex financial instruments, including warrants and redeemable shares. Management described remediation efforts, but gave no assurance they would be effective. Disclosure controls were assessed as effective.
- The filing cites risks to completing the transaction, obtaining financing, meeting closing and redemption conditions, and preserving trust funds against creditor claims. It also discusses potential adverse effects from COVID-19 and the Russia-Ukraine conflict; their specific impact was not determinable.
- There were no reported operating-business guidance or revenue forecasts. The company said it intended to complete the Nukkleus transaction or obtain an extension; failure to do so could result in liquidation. Public rights and warrants could expire worthless if no combination is completed.
Key investor verification points
- Confirm the issuer: the filing is for Brilliant Acquisition Corporation, while the request identifies T3 Defense Inc.
- Check the latest status and terms of the Nukkleus merger agreement, subsequent amendments, required approvals, financing, and any eventual transaction outcome.
- Verify the business-combination deadline, extension deposits, post-year-end redemptions, and current trust balance; the filing contains multiple dates and figures relating to extensions.
- Review related-party notes and advances, repayment terms, and the availability of additional funding; funding support is not assured.
- Assess the going-concern warning, trust-account creditor exposure, sponsor indemnity capacity, and remediation of the material weakness in financial reporting controls.